key: cord-0806724-gwehjyu8
authors: Abdul-Latif, M. A.; English, S.; Fernandes, J.; Singer, J.; Chowdhury, S.; Anand, G.
title: Radical radiotherapy (RT) and chemoradiotherapy (CRT) in non-small cell lung cancer (NSCLC): Outcomes from a regional cancer network
date: 2020-09-30
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2020.08.127
sha: 70759f2fb9eef6169e93a706584fa6ad886c7a10
doc_id: 806724
cord_uid: gwehjyu8

nan

Methods: Data for patients who received RT or CRT for Stage I-III NSCLC from 2016-2018 (prior to introduction of adjuvant Durvalumab e NICE approved in 2018) was reviewed at North Middlesex University Hospital, London. Data included smoking history, lung function, planning parameters (PTV, Mean heart dose (MHD), V20 and V5 lung), relapses and deaths. Outcomes were demonstrated as overall survival (OS) and progression free survival (PFS) through Kaplan-Meier analyses. Progression was defined from follow-up imaging or clinical documentation.

Results: 90 patients were analysed. Median follow-up time was 16 months. Median age was 72. 60 patients received 55Gy (66%) and 30 received 60-66Gy (33%). 32 patients received concurrent CRT (cCRT-36%), 13 received sequential CRT (sCRT-14%) and 45 received RT alone (50%). 21 patients had early disease (Stage I+II,23%) and 69 had Stage III disease (77%). Median PTV was 304 mm 3 and median MHD was 6.65Gy. For all patients, median OS (mOS) was 23 months. Median PFS (mPFS) was 12 months. 1, 2 and 3 year OSR was 72%, 47% and 30% respectively. In those aged over 70, mOS was 23 months and mPFS was 12. For cCRT, mOS was 26 months and mPFS was 14. For sCRT, mOS was 13 months and mPFS was 13. RT alone mOS was 22 months and mPFS was 10. mOS for the cCRT group using 60-66Gy was 26 months and was not reached for 55Gy. mPFS for 60-66Gy and 55Gy was 12 and 15 months respectively. In those aged over 70-1,2 and 3 year OSR was 83%,70% and 50% respectively. FEV1% predicted was associated with OS (HR 0.98, 95% CI 0.97-0.99, p¼0.04). Further analysis was performed looking at smoking history, performance status, pathology and gender.

Conclusions: Our data confirms that cCRT is an effective treatment for NSCLC (regardless of schedule and age) with comparable outcomes to contemporary CRT trials. Patient screening and regimen choice is key to good outcomes, as apparent in the trends within our data.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding. 1256TiP Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012

Grosshansdorf, Germany Background: Pembro, an anti-PD-1 antibody is standard of care therapy for metastatic NSCLC as monotherapy and in combination with chemotherapy. Durva, an antiePD-L1 antibody, is approved for unresectable, stage III NSCLC without disease progression (PD) following CCRT. Early trials of pembro in combination with CRT, either concurrent or as consolidation, showed acceptable tolerability and promising PFS in patients (pts) with unresectable stage III NSCLC. Early data suggest the combination of poly(ADP-ribose) polymerase (PARP) + antiePD-(L)1 inhibition can enhance treatment effects. KEYLYNK-012 (NCT04380636) evaluates pembro + CCRT followed by pembro with/without the PARP inhibitor ola vs CCRT followed by durva in pts with unresectable, locally advanced, stage III NSCLC. Trial design: This global phase 3, randomized, placebo-and active-controlled, doubleblind study will enroll pts aged !18 y with previously untreated, pathologically confirmed, stage IIIAeC NSCLC, ECOG PS 0/1, and tumor sample available for PD-L1 evaluation